Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000799995 | SCV000939690 | likely benign | Tuberous sclerosis 1 | 2025-01-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440669 | SCV002741494 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-14 | criteria provided, single submitter | clinical testing | The p.S91L variant (also known as c.272C>T), located in coding exon 3 of the TSC1 gene, results from a C to T substitution at nucleotide position 272. The serine at codon 91 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002487685 | SCV002790061 | uncertain significance | Lymphangiomyomatosis; Tuberous sclerosis 1; Isolated focal cortical dysplasia type II | 2021-11-11 | criteria provided, single submitter | clinical testing | |
St. |
RCV000799995 | SCV005689343 | uncertain significance | Tuberous sclerosis 1 | 2024-07-25 | criteria provided, single submitter | clinical testing | The TSC1 c.272C>T (p.Ser91Leu) missense change has a maximum subpopulation frequency of 0.00088% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but this prediction has not been confirmed by functional studies. This variant has not been reported in individuals with tuberous sclerosis complex. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |